Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 2Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 12Other hematologic neoplasm 9Thoracic 8Lymphoid 6Gynecologic 5CNS 5Breast 4Tumor-Agnostic 3Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1Endocrine 1Classical hematology 1

Conditions

Melanoma 2

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Observation × Dermatologic × Clear all
NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
1,150 enrolled 6 charts
Dermatologic

Melanoma

NCT00004196 2014-01-20

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

University of Alabama at Birmingham

Phase 3 Completed
3,000 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡